BidaskClub upgraded shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) from a buy rating to a strong-buy rating in a research note published on Wednesday.

Other equities research analysts also recently issued reports about the company. Cantor Fitzgerald reissued a buy rating and issued a $21.00 price objective on shares of Abeona Therapeutics in a research note on Tuesday, June 6th. Jefferies Group LLC reissued a buy rating and set a $11.00 price objective on shares of Abeona Therapeutics in a report on Thursday, June 1st. FBR & Co reiterated a buy rating on shares of Abeona Therapeutics in a research report on Friday, May 26th. Maxim Group set a $14.00 target price on Abeona Therapeutics and gave the stock a buy rating in a research report on Thursday, May 25th. Finally, Zacks Investment Research raised Abeona Therapeutics from a hold rating to a buy rating and set a $10.00 price target on the stock in a research report on Tuesday, July 11th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $17.43.

Abeona Therapeutics (NASDAQ:ABEO) opened at 8.90 on Wednesday. Abeona Therapeutics has a 52-week low of $2.33 and a 52-week high of $9.85. The firm’s market capitalization is $358.27 million. The firm’s 50-day moving average is $5.54 and its 200-day moving average is $5.24.

Abeona Therapeutics (NASDAQ:ABEO) last announced its earnings results on Thursday, May 18th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.02. Abeona Therapeutics had a negative return on equity of 26.99% and a negative net margin of 2,568.57%. The business had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. On average, analysts anticipate that Abeona Therapeutics will post ($0.56) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Abeona Therapeutics Inc. (ABEO) Upgraded by BidaskClub to “Strong-Buy”” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dailypolitical.com/2017/07/17/abeona-therapeutics-inc-abeo-upgraded-by-bidaskclub-to-strong-buy.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in Abeona Therapeutics by 869.7% in the first quarter. Goldman Sachs Group Inc. now owns 116,000 shares of the biopharmaceutical company’s stock valued at $580,000 after buying an additional 104,038 shares in the last quarter. Family Management Corp purchased a new position in shares of Abeona Therapeutics during the first quarter valued at approximately $120,000. Highbridge Capital Management LLC increased its position in shares of Abeona Therapeutics by 23.5% in the first quarter. Highbridge Capital Management LLC now owns 681,611 shares of the biopharmaceutical company’s stock valued at $3,408,000 after buying an additional 129,811 shares during the period. Geode Capital Management LLC increased its position in shares of Abeona Therapeutics by 2.4% in the first quarter. Geode Capital Management LLC now owns 196,073 shares of the biopharmaceutical company’s stock valued at $980,000 after buying an additional 4,588 shares during the period. Finally, Segantii Capital Management Ltd increased its position in shares of Abeona Therapeutics by 564.6% in the first quarter. Segantii Capital Management Ltd now owns 33,894 shares of the biopharmaceutical company’s stock valued at $169,000 after buying an additional 28,794 shares during the period. Institutional investors own 35.60% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.